THCV Lowered Blood Sugar in Type 2 Diabetes Patients in a Groundbreaking Pilot Trial
In a randomized pilot trial of 62 type 2 diabetes patients, the minor cannabinoid THCV significantly lowered fasting blood sugar and improved pancreatic beta-cell function, while CBD had more modest effects.
Quick Facts
What This Study Found
This was the first randomized controlled trial testing cannabinoids specifically for glycemic control in type 2 diabetes. Sixty-two patients with non-insulin-treated diabetes were randomized to five groups: CBD alone, THCV alone, low-ratio CBD:THCV, high-ratio CBD:THCV, or placebo for 13 weeks.
THCV was the clear standout. Compared to placebo, it significantly decreased fasting blood sugar, improved pancreatic beta-cell function, increased the beneficial hormone adiponectin, and improved apolipoprotein A levels. However, it did not affect HDL cholesterol (the primary endpoint).
CBD showed more modest effects, decreasing the inflammatory marker resistin and increasing the gut hormone GIP compared to baseline, but these changes were not significant compared to placebo.
Surprisingly, the combination treatments (CBD plus THCV) had no significant impact on any endpoint, suggesting the compounds may interfere with each other.
Key Numbers
THCV decreased fasting glucose by 1.2 mmol/L vs. placebo (p<0.05). Beta-cell function improved by 44.51 points (p<0.01). Adiponectin increased (p<0.01). CBD decreased resistin by 898 pg/ml (p<0.05 vs. baseline). 62 patients, 13-week treatment. Both compounds were well-tolerated.
How They Did This
Randomized, double-blind, placebo-controlled, parallel-group pilot study. Sixty-two subjects with non-insulin-treated type 2 diabetes across five treatment arms for 13 weeks. CBD was dosed at 100 mg twice daily and THCV at 5 mg twice daily. Primary endpoint: HDL cholesterol change. Extensive secondary and tertiary metabolic endpoints.
Why This Research Matters
THCV is a minor cannabinoid found in small amounts in some cannabis varieties. This trial provides the first human evidence that it has genuine metabolic effects in diabetes patients. If confirmed in larger trials, THCV could represent an entirely new class of diabetes medication derived from cannabis.
The Bigger Picture
Type 2 diabetes affects hundreds of millions of people globally. The discovery that a cannabis-derived compound can improve blood sugar control and beta-cell function in humans is significant, especially because THCV is non-psychoactive. The failure of the combinations is also important, as it suggests that more is not always better with cannabinoid therapeutics.
What This Study Doesn't Tell Us
Small pilot study (62 patients across 5 arms means very small per-group sizes). The primary endpoint (HDL) was not met. Thirteen weeks may be too short to see full metabolic effects. THCV is available in very limited quantities, which would constrain clinical development.
Questions This Raises
- ?Would larger, longer THCV trials confirm these findings?
- ?Why did the CBD-THCV combinations fail to show effects?
- ?Could THCV be developed as a diabetes medication if supply challenges are overcome?
Trust & Context
- Key Stat:
- THCV lowered fasting blood sugar by 1.2 mmol/L and improved beta-cell function
- Evidence Grade:
- Randomized double-blind placebo-controlled trial, but small pilot study with multiple arms resulting in very small group sizes.
- Study Age:
- Published in 2016. THCV research for metabolic conditions remains in early stages due to limited compound availability.
- Original Title:
- Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
- Published In:
- Diabetes care, 39(10), 1777-86 (2016)
- Authors:
- Jadoon, Khalid A, Ratcliffe, Stuart H, Barrett, David A(3), Thomas, E Louise, Stott, Colin, Bell, Jimmy D, O'Sullivan, Saoirse E, Tan, Garry D
- Database ID:
- RTHC-01183
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Can cannabis lower blood sugar?
In this pilot trial, the specific cannabinoid THCV (not THC) significantly lowered fasting blood sugar in type 2 diabetes patients. This is a minor compound found in small amounts in some cannabis varieties, not the main psychoactive ingredient.
Does CBD help with diabetes?
CBD showed modest effects on some inflammatory and hormonal markers compared to baseline, but these changes were not significant compared to placebo. THCV showed much stronger metabolic effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01183APA
Jadoon, Khalid A; Ratcliffe, Stuart H; Barrett, David A; Thomas, E Louise; Stott, Colin; Bell, Jimmy D; O'Sullivan, Saoirse E; Tan, Garry D. (2016). Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.. Diabetes care, 39(10), 1777-86. https://doi.org/10.2337/dc16-0650
MLA
Jadoon, Khalid A, et al. "Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.." Diabetes care, 2016. https://doi.org/10.2337/dc16-0650
RethinkTHC
RethinkTHC Research Database. "Efficacy and Safety of Cannabidiol and Tetrahydrocannabivari..." RTHC-01183. Retrieved from https://rethinkthc.com/research/jadoon-2016-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.